Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

Published:2024-07-03 Issue:8 Volume:41 Page:3039-3058
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

De Santis Maria,Breijo Sara Martínez,Robinson Paul,Capone Camille,Pascoe Katie,Van Sanden Suzy,Hashim Mahmoud,Trevisan Marco,Daly Caitlin,Reitsma Friso,van Beekhuizen Sophie,Ruan Haoyao,Heeg Bart,Verzoni Elena

Funder

Cilag

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-024-02918-6.pdf

Reference48 articles.

1. Wang L, et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10: 811044.

2. Inamura K. Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. Oncotarget. 2018;9(18):14723–37.

3. Akaza H, et al. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry. J Glob Oncol. 2018;4:1–12.

4. Chi KN, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41(18):3339–51.

5. de Bono J, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–102.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational Analysis of Treatment Resistant Cancer Cells;2024-08-31

2. Quantitative Microscopy in Medicine;2024-08-03